Cargando…

Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study

Ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (OAML) is the most common type of ocular lymphoma with a higher prevalence in Asia than in Western countries. OAML represents 1%–2% of all non-Hodgkin’s lymphoma, 5%–15% of extranodal lymphomas, and approximately 55% of orbital maligna...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Gi-June, Kim, Sung Eun, Kim, Tong Yoon, Jeon, Young-Woo, O, Joo Hyun, Choi, Byung-Ock, Park, Gyeongsin, Yang, Suk-Woo, Cho, Seok-Goo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120944/
https://www.ncbi.nlm.nih.gov/pubmed/35600403
http://dx.doi.org/10.3389/fonc.2022.769530
_version_ 1784711047233404928
author Min, Gi-June
Kim, Sung Eun
Kim, Tong Yoon
Jeon, Young-Woo
O, Joo Hyun
Choi, Byung-Ock
Park, Gyeongsin
Yang, Suk-Woo
Cho, Seok-Goo
author_facet Min, Gi-June
Kim, Sung Eun
Kim, Tong Yoon
Jeon, Young-Woo
O, Joo Hyun
Choi, Byung-Ock
Park, Gyeongsin
Yang, Suk-Woo
Cho, Seok-Goo
author_sort Min, Gi-June
collection PubMed
description Ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (OAML) is the most common type of ocular lymphoma with a higher prevalence in Asia than in Western countries. OAML represents 1%–2% of all non-Hodgkin’s lymphoma, 5%–15% of extranodal lymphomas, and approximately 55% of orbital malignancies. “Watch and wait” after biopsy or surgical resection, radiation therapy, and systemic treatment, including antibiotics administration and chemotherapy with various combinations of regimens can be considered for OAML treatment. Radiotherapy is adapted for limited-stage disease with excellent clinical outcomes of 85–100% complete remission and relatively superior local control efficacy and treatment duration. In contrast, chemotherapy has rarely been tested as frontline therapy. Nonetheless, several studies have reported a favorable response and long duration of progression-free survival using chemotherapy adaptations. When the disease involves both eyes or spreads beyond the conjunctiva, the risk of recurrence increases and limited-stage OAML has a recurrence rate of approximately 25% following radiotherapy only. Therefore, although recent consensus in the literature is that patients with limited-stage OAML recommended treating with radiation, physicians may choose the treatment modality not only by its efficiency but also by its adverse events profile and patients’ well-being. Herein, we present a large single-center study on OAML that included 292 patients who were followed up for up to 237 months. We collected and analyzed real-world data focusing on treatment outcomes and the role of radiotherapy as frontline therapy, and aimed to compare outcomes and complication profiles of chemotherapy, especially in limited-stage OAML, to identify an optimal treatment strategy.
format Online
Article
Text
id pubmed-9120944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91209442022-05-21 Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study Min, Gi-June Kim, Sung Eun Kim, Tong Yoon Jeon, Young-Woo O, Joo Hyun Choi, Byung-Ock Park, Gyeongsin Yang, Suk-Woo Cho, Seok-Goo Front Oncol Oncology Ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (OAML) is the most common type of ocular lymphoma with a higher prevalence in Asia than in Western countries. OAML represents 1%–2% of all non-Hodgkin’s lymphoma, 5%–15% of extranodal lymphomas, and approximately 55% of orbital malignancies. “Watch and wait” after biopsy or surgical resection, radiation therapy, and systemic treatment, including antibiotics administration and chemotherapy with various combinations of regimens can be considered for OAML treatment. Radiotherapy is adapted for limited-stage disease with excellent clinical outcomes of 85–100% complete remission and relatively superior local control efficacy and treatment duration. In contrast, chemotherapy has rarely been tested as frontline therapy. Nonetheless, several studies have reported a favorable response and long duration of progression-free survival using chemotherapy adaptations. When the disease involves both eyes or spreads beyond the conjunctiva, the risk of recurrence increases and limited-stage OAML has a recurrence rate of approximately 25% following radiotherapy only. Therefore, although recent consensus in the literature is that patients with limited-stage OAML recommended treating with radiation, physicians may choose the treatment modality not only by its efficiency but also by its adverse events profile and patients’ well-being. Herein, we present a large single-center study on OAML that included 292 patients who were followed up for up to 237 months. We collected and analyzed real-world data focusing on treatment outcomes and the role of radiotherapy as frontline therapy, and aimed to compare outcomes and complication profiles of chemotherapy, especially in limited-stage OAML, to identify an optimal treatment strategy. Frontiers Media S.A. 2022-05-06 /pmc/articles/PMC9120944/ /pubmed/35600403 http://dx.doi.org/10.3389/fonc.2022.769530 Text en Copyright © 2022 Min, Kim, Kim, Jeon, O, Choi, Park, Yang and Cho https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Min, Gi-June
Kim, Sung Eun
Kim, Tong Yoon
Jeon, Young-Woo
O, Joo Hyun
Choi, Byung-Ock
Park, Gyeongsin
Yang, Suk-Woo
Cho, Seok-Goo
Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study
title Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study
title_full Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study
title_fullStr Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study
title_full_unstemmed Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study
title_short Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study
title_sort long-term clinical outcomes in treatment-naïve patients with orbital adnexal mucosa-associated lymphoid tissue lymphoma: a single-center study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120944/
https://www.ncbi.nlm.nih.gov/pubmed/35600403
http://dx.doi.org/10.3389/fonc.2022.769530
work_keys_str_mv AT mingijune longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT kimsungeun longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT kimtongyoon longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT jeonyoungwoo longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT ojoohyun longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT choibyungock longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT parkgyeongsin longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT yangsukwoo longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy
AT choseokgoo longtermclinicaloutcomesintreatmentnaivepatientswithorbitaladnexalmucosaassociatedlymphoidtissuelymphomaasinglecenterstudy